Gritstone reports Q1 cash $52.8M; GRANITE Phase 2 MSS-CRC shows favorable PFS trend (HR 0.82 overall, 0.52 high-risk)

Gritstone bio, Inc.

2024-Q1 EPS reported -$0.34 revenue$1,742,000

Cash, equivalents and marketable securities $52.8M as of March 31, 2024, down from $86.9M at Dec 31, 2023.
Preliminary Phase 2 GRANITE data: PFS hazard ratio 0.82 overall (95% CI 0.34-1.67) and 0.52 in high-risk group (95% CI 0.15-1.38); mature data expected Q3 2024.
Completed public offering in April 2024 for gross proceeds of $32.5M; appointed Stephen Webster to Board.
R&D expenses $33.0M, G&A $8.5M for Q1 2024; collaboration & grant revenue $1.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Gritstone bio, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Gritstone bio, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024 and provided a business update.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-056916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.